Sana is a pure pipeline story — the Q1 results are directionally neutral as losses narrowed slightly and cash runway extended. The key catalysts are IND filings and Phase 1 starts for SC451 and SG293 later this year. Watch for ASGCT presentation on May 12 for SG293 preclinical data. The Mayo collaboration provides validation but the stock will move on clinical data, not financials.
Price Chart
Executive Summary
Sana Biotechnology reported Q1 2026 results with a GAAP net loss of $0.17 per share, narrower than the $0.21 loss in Q1 2025, but the company remains a pre-revenue biotech with no approved products. Cash burn continues at ~$37M/quarter, and the cash runway was extended into 2027 via a $25M equity investment from Mayo Clinic as part of a strategic collaboration. The stock will trade on pipeline catalysts — IND filings for SC451 and SG293 expected later this year — rather than financial results.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP net loss of $47.2M ($0.17/share) vs $49.4M ($0.21/share) in Q1 2025
- Cash position of $101.1M at March 31, 2026, down from $138.4M at December 31, 2025
- Pro forma cash of $128.9M including $25M equity investment from Mayo Clinic collaboration
- Non-GAAP operating cash burn of $37.0M in Q1 2026 vs $46.6M in Q1 2025
- Mayo Clinic made a $25M equity investment with option for an additional $25M
- Expects to file IND and begin Phase 1 trial for SC451 (type 1 diabetes) later this year
- Expects to begin clinical study for SG293 (non-Hodgkin lymphoma) later this year
- SG227 (BCMA-targeted CAR T) expected to begin clinical testing as early as mid-2027
- UP421 study showed ongoing islet cell survival and function at 14 months post-transplant
- No revenue — pre-recovery biotech with no approved products
Financial Impact
Q1 2026 net loss of $47.2M, cash burn of $37.0M, cash runway extended into 2027 via $25M equity investment
Risk Factors
- Pre-revenue biotech with no approved products — entirely dependent on clinical trial success
- Cash runway only into 2027 — likely to need additional financing before data readouts
- Clinical trial delays or negative data could severely impact stock price
- Dilution risk from ongoing ATM and potential future equity offerings
- Contingent consideration liabilities of $151.4M could materially impact balance sheet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-216758 |
| Document: sana-20260511.htm | 0001193125-26-216758 |
| Document: 0001193125-26-216758-index-headers.html | 0001193125-26-216758 |
| Document: 0001193125-26-216758-index.html | 0001193125-26-216758 |
| Document: 0001193125-26-216758.txt | 0001193125-26-216758 |
| 8-K Data (Synthetic) | 0001193125-26-216758 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
Aug 10, 2026 7w ago | Press Release | $3.79 $3.17 | ▼ −16.36% | ▼ −15.30% | $2.87 (−24.41%) |
May 11, 2026 20w ago | 8-K | $3.26 $2.82 | ▼ −13.50% | ▼ −11.77% | $2.87 (−12.12%) |
May 11, 2026 20w ago | Press Release | $3.26 $2.82 | ▲ +13.50% | ▲ +11.77% | $2.87 (+12.12%) |
Apr 24, 2026 23w ago | DEFA14A | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 24, 2026 23w ago | 8-K | $3.29 $3.15 | ▼ −4.26% | ▼ −8.28% | $2.87 (−12.92%) |
Apr 13, 2026 24w ago | 8-K | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Apr 13, 2026 24w ago | Press Release | $3.48 $3.56 | ▲ +2.30% | ▼ −4.00% | $2.87 (−17.67%) |
Mar 13, 2026 29w ago | Press Release | $3.36 $3.21 | ▼ −4.46% | ▼ −8.05% | $2.87 (−14.73%) |
Mar 3, 2026 30w ago | Press Release | $3.82 $3.05 | ▼ −20.16% | ▼ −15.74% | $2.87 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access